Startup · $27.6m raised
Houston
Every investor coverage indicates participated in a round BiVACOR raised.
| Investor | Rounds | Invested |
|---|---|---|
| OneVentures | Series A | - |
Companies BiVACOR acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Daniel Timms | CEO | SmartCompany, @AuManufacturing |
Stories naming BiVACOR. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
AFR reports the titanium artificial heart maker is chasing $100 million for trials after a Sydney patient spent three months on the device; OneVentures is named as a backer.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
Weekly roundup of readers' top five stories: Gilmour Space's $55m Series D raise, a $50m MRFF grant for an artificial heart consortium, K-TIG entering administration, defence budget news, and Queensland's return to venture investing.
A OneVentures blog post linking to Sky News coverage of an Australian engineer's artificial heart invention, plus a related item on US regulatory clearance for BiVACOR's heart device human trial.
The federal MRFF has granted $50 million to the Artificial Heart Frontiers Program, a Monash-led consortium including BiVACOR, to advance a total artificial heart; the team earlier received $1 million in 2021.
Also @AuManufacturing
US regulators cleared first-in-human testing of BiVACOR's total artificial heart; the OneVentures page also links earlier coverage and the Biomedical Translation Fund's investment in the device.
OneVentures' blog post pointing readers to Financial Review coverage of the firm and the artificial-heart developer BiVACOR; the post itself contains no deal details.
A consortium led by Monash University and BiVACOR won a $1 million Medical Research Future Fund grant to commercialise an Australian total artificial heart; BiVACOR had earlier closed a US$19 million Series B.
OneVentures appoints Jim Scopa and Dan Baker to its healthcare investment team, and recalls its Healthcare Fund III backing Blade Therapeutics and BiVACOR.